Form 4: Humacyte Director's Spouse Acquires Shares, Triggering Section 16(b) Match

A spouse of a Humacyte director purchased 1,797 shares of common stock, triggering a matchable transaction under Section 16(b) of the Securities Exchange Act of 1934.

Summary

• Brady W. Dougan, a director at Humacyte, Inc., had a transaction reported on his behalf.
• His spouse purchased 1,797 shares of Humacyte common stock at a weighted average price of $4.44 per share on November 19, 2024.
• This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934 against a prior sale by Ayabudge LLC, an entity controlled by Mr. Dougan.
• The spouse paid Humacyte $8,778.23, representing the full profit realized from the matchable transaction.
• Following the transaction, Mr. Dougan beneficially owns 510,161 shares directly, 1,730,884 shares indirectly through Ayabudge LLC, and 1,148,240 shares indirectly through The Niklason Living Trust.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to insider trading. It doesn't indicate any significant positive or negative sentiment about the company's performance or future prospects.

Positives

• The spouse's purchase demonstrates confidence in the company's stock.
• The payment of $8,778.23 to the company ensures compliance with Section 16(b) regulations.

Negatives

• The transaction was triggered by a matchable sale by an entity controlled by the director, indicating a prior sale of shares.
• The need for a Section 16(b) payment suggests a potential short-swing profit situation.

Risks

• The transaction highlights the complexities of insider trading regulations and the potential for inadvertent violations.
• Future transactions by insiders will need to be carefully monitored to avoid similar situations.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the biotechnology industry. It highlights the importance of compliance with securities regulations for company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, particularly in the biotech sector where insider trading is closely monitored.
• The transaction is similar to other filings where directors or officers report changes in their beneficial ownership of company stock.
• The Section 16(b) matchable transaction is a common occurrence when insiders have short-swing profits, and the payment to the company is a standard remedy.

Related Party Transactions

• The transaction involves a purchase by the spouse of a director and a matchable sale by Ayabudge LLC, an entity controlled by the director.

Stakeholder Impact

• The transaction has a minor impact on shareholders, as it is a routine disclosure of insider activity.
• The payment of $8,778.23 to the company is a small positive for the company's financials.

Key Dates

Keywords

Humacyte, insider trading, Section 16(b), beneficial ownership, Form 4, stock purchase, director, Ayabudge LLC, Niklason Living Trust